How to administrate erythropoietin, intravenous or subcutaneous?

Costa, Simonetta; Romagnoli, Costantino; Zuppa, Antonio Alberto; Cota, Francesco; Scorrano, Antonio; Gallini, Francesca; Maggio, Luca

doi:10.1111/apa.12193

Cited by 15 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant erythropoietin (rhEPO) is an example of a drug commonly administered subcutaneously; however, subcutaneous administration of rhEPO requires injection three times a week, a likely cause of discomfort for the neonate [79,80].…”

Section: Subcutaneousmentioning

confidence: 99%

“…Additionally, it has been observed that the drug can sometimes leak from the depot formed at the injection site [80]. This issue may be compounded by the relatively smaller proportion of subcutaneous fat in neonates compared with adults [15].…”

Section: Subcutaneousmentioning

confidence: 99%

“…This issue may be compounded by the relatively smaller proportion of subcutaneous fat in neonates compared with adults [15]. Based on these concerns, Costa et al examined the use of intravenous fluids for erythropoietin delivery and concluded that 24-h intravenous infusion of erythropoietin was not inferior to subcutaneous injection and therefore provides a potentially easier alternative in neonates who already have central line access [80]. It is important to note that this study had some limitations, including the use of subcutaneous treatment after the central line was removed from a neonate.…”

Section: Subcutaneousmentioning

confidence: 99%

See 2 more Smart Citations

Challenges Associated with Route of Administration in Neonatal Drug Delivery

et al. 2015

View full text Add to dashboard Cite

The administration of drugs to neonates poses significant challenges. The aim of this review was to provide insight into some of these challenges and resolutions that may be encountered with several of the most commonly used routes of administration and dosage forms in neonatal care, including oral, parenteral, transdermal, intrapulmonary, and rectal. Important considerations include fluctuations in stomach pH hours to years after birth, the logistics of setting up an intravenous infusion, the need for reduced particle size for aerosol delivery to the developing neonatal lung, and variation in perirectal venous drainage. Additionally, some of the recently developed technologies for use in neonatal care are described. While the understanding of neonatal drug delivery has advanced over the past several decades, there is still a deficiency of technologies and formulations developed specifically for this population.

show abstract

Section: Subcutaneousmentioning

confidence: 99%

Section: Subcutaneousmentioning

confidence: 99%

Section: Subcutaneousmentioning

confidence: 99%

See 1 more Smart Citation

Challenges Associated with Route of Administration in Neonatal Drug Delivery

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Only 1 study in this meta-analysis reported an increase in ROP among recipients of Epo, a single-center study by Romagnoli et al 14 In revised meta-analyses 15,16 of the 27 studies randomizing 2209 infants to early Epo or placebo, the incidence of ROP was reported in 7 studies, comprising only 36% of all study infants. Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit. 17 …”

mentioning

confidence: 99%

“…Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit. 17 …”

mentioning

confidence: 99%